Avastin Phase III Trial Meets Endpoint: PFS in Platinum-Sensitive Ovarian Cancer
Iniparib Doesn’t Meet Survival, PFS Endpoints In Phase III Trial in Triple-Negative Breast Cancer
Sentinel Node Disection No Worse Than Axillary
Triple-Negative Breast Cancer Equally Aggressive in Whites
RG7204 Meets Endpoints Of Extending Survival, PFS
INSPIRE Enrollment Stopped; Thromboembolism Risk Cited
Tarceva Reaches Endpoint Early: Longer PFS Than Chemo Alone
mTOR Inhibitor Improves PFS In Metastatic Sarcoma Patients
Afinitor Tablet Doubles PFS; Lowers Progression Risk 65%
Study Links Native American Ancestry to Leukemia Relapse
Study Explores Reasons Women Avoid Mammograms
Hormone Therapy At Menopause Linked to More Breast Cancer Risk
Children of Male Cancer Survivors Have Highrt Risk of Birth Defects
Study Finds No Link Between Tumor Grade and Relapse Risk
Clinical Trials Approved By NCI CTEP Last Month
Rituxan Approved as Maintenance For Advanced Follicular Lymphoma
Trending Stories
- Beyond the $500B Stargate Project: The frontier of AI in oncology beckons
- Trump 2016: A look back at the 45th president’s impact on oncology
- What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - Felix Feng, GU cancer researcher who made fundamental discoveries in genomics, dies at 48
- Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills - Rooting out the “illegal and immoral discrimination” of DEI is the first order of business for Trump
